Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
very very possible! this volume is huge!
Volume precedes price...this amount of volume = a lot of green to come!
massive volume today..just blows out all the rest of the days
very nice bounce off of the dip today, pastor. very good rebound!
great addition to a very prominent scientific team already!
Looks like a great team they are building!
SPPH INFO
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
SPPH INFO
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
SPPH corporate video
http://www.spencerpharmaceutical.com/index.php?pg=video&cat=company
SPPH Corporate Video!
http://www.spencerpharmaceutical.com/index.php?pg=video&cat=company
SPPH having a breakout volume today! great bounce off the dip!
SPPH has some breakout volume! huge volume today!
nice movement today! great volume!
SPPH NEWS!
Spencer Pharmaceutical Inc. Announces Dr. Abderrazzak Merzouki Joins the Scientific Advisory Board and Business Advisor
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.33 +0.01
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical, Inc. On Thursday October 28, 2010, 6:15 am EDT
BOSTON, MA--(Marketwire - 10/28/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today the addition of Dr. Abderrazzak Merzouki to join its Scientific Advisory Board as well as accepting a position as a business advisor with the company.
The management of Spencer Pharmaceutical Inc. is delighted to announce the addition of Dr. Merzouki to the Scientific Advisory Board. He brings a wealth of scientific research knowledge to the team. Dr. Merzouki is a research scientist and professor of Virology-Immunology.
He is currently teaching and lecturing at the Institute of Biomedical Engineering (Department of Chemical Engineering) at Ecole Polytechnique de Montreal since 2007 as a senior scientist where he currently manages a suite of molecular and cell biology laboratories.
"Dr. Merzouki is a molecular biologist and an immunologist with a long experience in the gene therapy area where he has performed several preclinical and clinical analysis for pharmaceutical companies involving the use of adenoviral vectors for cancer (Introgen Therapeutics Inc., USA Gencell Asia/Pacific, Japan) and DNA plasmid vectors for peripheral artery occlusive disease (Aventis Pharma, France/USA). Dr. Merzouki has an extensive expertise in the design of expressing vectors, production and purification of recombinants proteins. He developed technologies (Patents pending) for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis," stated Dr. Max Arella, CEO and Chairman of Spencer Pharmaceutical Inc. "We are pleased that Dr. Merzouki has accepted to serve Spencer Pharmaceutical as a scientific and business advisor. His extensive network in scientific and businesses circles in the Middle East/North Africa regions will certainly be a major asset for our company in future negotiations in this part of the world," concluded Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information
About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
SPPH NEWS!
Spencer Pharmaceutical Inc. Announces Dr. Abderrazzak Merzouki Joins the Scientific Advisory Board and Business Advisor
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.33 +0.01
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical, Inc. On Thursday October 28, 2010, 6:15 am EDT
BOSTON, MA--(Marketwire - 10/28/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today the addition of Dr. Abderrazzak Merzouki to join its Scientific Advisory Board as well as accepting a position as a business advisor with the company.
The management of Spencer Pharmaceutical Inc. is delighted to announce the addition of Dr. Merzouki to the Scientific Advisory Board. He brings a wealth of scientific research knowledge to the team. Dr. Merzouki is a research scientist and professor of Virology-Immunology.
He is currently teaching and lecturing at the Institute of Biomedical Engineering (Department of Chemical Engineering) at Ecole Polytechnique de Montreal since 2007 as a senior scientist where he currently manages a suite of molecular and cell biology laboratories.
"Dr. Merzouki is a molecular biologist and an immunologist with a long experience in the gene therapy area where he has performed several preclinical and clinical analysis for pharmaceutical companies involving the use of adenoviral vectors for cancer (Introgen Therapeutics Inc., USA Gencell Asia/Pacific, Japan) and DNA plasmid vectors for peripheral artery occlusive disease (Aventis Pharma, France/USA). Dr. Merzouki has an extensive expertise in the design of expressing vectors, production and purification of recombinants proteins. He developed technologies (Patents pending) for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis," stated Dr. Max Arella, CEO and Chairman of Spencer Pharmaceutical Inc. "We are pleased that Dr. Merzouki has accepted to serve Spencer Pharmaceutical as a scientific and business advisor. His extensive network in scientific and businesses circles in the Middle East/North Africa regions will certainly be a major asset for our company in future negotiations in this part of the world," concluded Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information
About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
SPPH NEWS!
Spencer Pharmaceutical Inc. Added to the IAB MCSC Index
marketwire
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.3390 +0.0140
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical, Inc. On Wednesday October 27, 2010, 2:18 pm
BOSTON, MA--(Marketwire - 10/27/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has been added to the ItsAllBull.net Micro Cap Small Cap (MCSC) Index. The MCSC Index is tracking the general performance of equities that trade primarily on the Over-the-Counter (OTC) markets including the Pinksheets, Bulletin Boards, as well as the TSX Venture Exchange. It has been over performing the Dow Jones and S&P TSX indices since its inception in September 2009.
You can view its performance at http://www.itsallbull.net/mcsc.php
"Clearly we are very pleased to be included in the IAB MCSC Index as it is very important to continually improve the company's profile and exposure," stated Dr. Max Arella, CEO of Spencer Pharmaceutical Inc.
About ItsAllBull.net:
Itsallbull.net is an online financial community forum aimed at providing financial information to money managers, individual investors and analysts. They offer a unique information service to the investment communities by offering Technical analysis and Corporate videos, Reports and Presentations, Corporate Governance on over 29,000 publicly Traded Companies. At its creation date on September 1, 2009, the IAB MCSC Index initially selected 2000 companies from the total number of equities listed on the above mentioned exchanges to include in the Index. Criteria used to select the Index component companies included; companies having a stock price of no more than $5.00, and stocks experiencing at least a minimal level of daily trading volume. Then for each stock selected for the MCSC Index portfolio, an initial position worth $10,000 USD was recorded. The IAB MCSC Index is reviewed and updated daily, and equities that no longer meet the inclusion criteria are removed and/or replaced. As delisting and name/symbol changes are common within the realm of the OTC markets, the actual number of equities listed in the MCSC Index will change frequently, and at any particular time may be less than 2000. Currently, the MCSC Index employs 1843 component companies.
About Spencer Pharmaceutical:
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Safe Harbor Statement:
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's contract manufacturers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
Contact:
Contact:
Dr. Max Arella
CEO/President
Spencer Pharmaceutical Inc.
Tel. (617) 973-5017
www.spencerpharmaceutical.com
SPPH NEWS!
Spencer Pharmaceutical Inc. Added to the IAB MCSC Index
marketwire
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.3390 +0.0140
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical, Inc. On Wednesday October 27, 2010, 2:18 pm
BOSTON, MA--(Marketwire - 10/27/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has been added to the ItsAllBull.net Micro Cap Small Cap (MCSC) Index. The MCSC Index is tracking the general performance of equities that trade primarily on the Over-the-Counter (OTC) markets including the Pinksheets, Bulletin Boards, as well as the TSX Venture Exchange. It has been over performing the Dow Jones and S&P TSX indices since its inception in September 2009.
You can view its performance at http://www.itsallbull.net/mcsc.php
"Clearly we are very pleased to be included in the IAB MCSC Index as it is very important to continually improve the company's profile and exposure," stated Dr. Max Arella, CEO of Spencer Pharmaceutical Inc.
About ItsAllBull.net:
Itsallbull.net is an online financial community forum aimed at providing financial information to money managers, individual investors and analysts. They offer a unique information service to the investment communities by offering Technical analysis and Corporate videos, Reports and Presentations, Corporate Governance on over 29,000 publicly Traded Companies. At its creation date on September 1, 2009, the IAB MCSC Index initially selected 2000 companies from the total number of equities listed on the above mentioned exchanges to include in the Index. Criteria used to select the Index component companies included; companies having a stock price of no more than $5.00, and stocks experiencing at least a minimal level of daily trading volume. Then for each stock selected for the MCSC Index portfolio, an initial position worth $10,000 USD was recorded. The IAB MCSC Index is reviewed and updated daily, and equities that no longer meet the inclusion criteria are removed and/or replaced. As delisting and name/symbol changes are common within the realm of the OTC markets, the actual number of equities listed in the MCSC Index will change frequently, and at any particular time may be less than 2000. Currently, the MCSC Index employs 1843 component companies.
About Spencer Pharmaceutical:
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Safe Harbor Statement:
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's contract manufacturers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
Contact:
Contact:
Dr. Max Arella
CEO/President
Spencer Pharmaceutical Inc.
Tel. (617) 973-5017
www.spencerpharmaceutical.com
NEWS!
Spencer Pharmaceutical Inc. Added to the IAB MCSC Index
marketwire
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.3390 +0.0140
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical, Inc. On Wednesday October 27, 2010, 2:18 pm
BOSTON, MA--(Marketwire - 10/27/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has been added to the ItsAllBull.net Micro Cap Small Cap (MCSC) Index. The MCSC Index is tracking the general performance of equities that trade primarily on the Over-the-Counter (OTC) markets including the Pinksheets, Bulletin Boards, as well as the TSX Venture Exchange. It has been over performing the Dow Jones and S&P TSX indices since its inception in September 2009.
You can view its performance at http://www.itsallbull.net/mcsc.php
"Clearly we are very pleased to be included in the IAB MCSC Index as it is very important to continually improve the company's profile and exposure," stated Dr. Max Arella, CEO of Spencer Pharmaceutical Inc.
About ItsAllBull.net:
Itsallbull.net is an online financial community forum aimed at providing financial information to money managers, individual investors and analysts. They offer a unique information service to the investment communities by offering Technical analysis and Corporate videos, Reports and Presentations, Corporate Governance on over 29,000 publicly Traded Companies. At its creation date on September 1, 2009, the IAB MCSC Index initially selected 2000 companies from the total number of equities listed on the above mentioned exchanges to include in the Index. Criteria used to select the Index component companies included; companies having a stock price of no more than $5.00, and stocks experiencing at least a minimal level of daily trading volume. Then for each stock selected for the MCSC Index portfolio, an initial position worth $10,000 USD was recorded. The IAB MCSC Index is reviewed and updated daily, and equities that no longer meet the inclusion criteria are removed and/or replaced. As delisting and name/symbol changes are common within the realm of the OTC markets, the actual number of equities listed in the MCSC Index will change frequently, and at any particular time may be less than 2000. Currently, the MCSC Index employs 1843 component companies.
About Spencer Pharmaceutical:
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Safe Harbor Statement:
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's contract manufacturers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
Contact:
Contact:
Dr. Max Arella
CEO/President
Spencer Pharmaceutical Inc.
Tel. (617) 973-5017
www.spencerpharmaceutical.com
would love to see what else is going on behind the scenes here...much more than what meets the eye i suspect! lot's of green to come in the near future!
i'm sure the company isn't slowing down the press machine...that thing has been cranking for the month of october! i expect more news to come!
SPPH Info
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
spread is looking a lot better than past days. interest is building!
SPPH RECENT NEWS!
http://www.spencerpharmaceutical.com/index.php?pg=quotes&cat=ir
More than 17 millions people in the United States have diabetes mellitus; most common is type 2 diabetes (90%). Type 2 diabetes is a condition characterized by high blood glucose levels caused by a lack of insulin or the body's inability to use insulin effectively. During the last decade, the prevalence of type 2 diabetes has significantly increased.
The most popular anti-diabetic drug for glycemia control in patients with type 2 diabetes is Metformin. In the United States, about 35 million prescriptions of genereic Metformin were issued in 2006.
In 2008, metformin is one of only two oral anti-diabetics in the World Health Organization Model List of Essential Medicines.
To our knowledge, monolithic tablet formatting for Metformin is a growing demand in the pharmaceutical world.
SPPH Corporate Video...check it out!
http://www.spencerpharmaceutical.com/index.php?pg=video&cat=company
Check out the corporate video if you haven't had the chance!
http://www.spencerpharmaceutical.com/index.php?pg=video&cat=company
Missions
Spencer is currently focusing on the development of 2 patented applications (ready for Human trial) in the treatment of Central Nervous System diseases and of Diabetes:
* L’Institut National des Sciences Appliquées de Rouen (INSA Rouen) has discovered a new technology in the challenging area of drugs delivered to the Central Nervous System through an innovative approach that allows the crossing of the blood-brain barrier and dramatically reducing the side effects of drugs used for neurological diseases.
* L’Universite du Québec à Montréal (UQAM) has discovered how to control the release of existing therapeutics molecules in order to increase their bio-availability and systemic efficacy.
Our goal is to develop a portfolio of pro-drugs with the ability to outclass the current commercial drugs. We aim to establish long-term, mutually beneficial relationships will all our partners and clients.
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
SPPH- only 45 million share float!
SPPH- great time to load up. this thing has been pumping gains out since June...more green coming
more gains and green are coming. we just need to be patient and we will definitely see some green
SPPH rebounding verrrrry nicely from this mornings dip!
looking mighty fine over here. this mornings dip has been bought up! loving the move back close to even!
we have an hour before power hour. Let's get over 100k before power hour, and we can see 150k at the end!
has been a splendid rebound from this mornings trading!
back up to the .30s..let's roll this baby green!
SPPH will see around 200k traded today IMO. Should get a real nice bounce from here
SPPH-i bought some on the dip definitely going to be worth a lot more later on today, and this week, and this month and next year!
due to the two PRs yesterday morning, around the same